An inherent T cell-activating mRNA delivery carrier for in vivo CAR T generation
Academic source · Nature Materials
Source published:
Site published: 2026-11-03 · Updated: 2026-11-04
This source is linked automatically. Choose a question to get started.
What the paper reports
A polymer-lipid carrier incorporating arginine-modified oligoethylenimine combined T-cell activation with mRNA delivery without an added targeting ligand. The formulation favored splenic delivery and engaged PI3K-AKT-mTOR signaling. FAP-CAR mRNA generated functional CAR T cells in experimental cancer and fibrosis settings. These are preclinical results; the article also has a subsequent publisher correction that should accompany interpretation.
Why this paper is included
Connects carrier biology to in vivo CAR-T generation; durable benefit, repeat-dose safety, and applicability to human T cells remain unresolved.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections